Palvella Therapeutics (NASDAQ:PVLA) Receives “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $39.00 price objective on the stock.

Other equities analysts have also issued research reports about the stock. TD Cowen assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Finally, Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Down 2.6 %

NASDAQ PVLA opened at $18.80 on Wednesday. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $22.32. The stock has a market cap of $210.95 million, a PE ratio of -1.55 and a beta of 0.68. The business has a 50 day moving average price of $14.62.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The shares were bought at an average price of $12.93 per share, with a total value of $51,720.00. Following the acquisition, the director now owns 180,671 shares in the company, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.39% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PVLA. Citadel Advisors LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at $125,000. Toronto Dominion Bank bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at $159,000. Geode Capital Management LLC purchased a new stake in Palvella Therapeutics during the 4th quarter valued at $171,000. Cresset Asset Management LLC purchased a new stake in Palvella Therapeutics during the 4th quarter valued at $251,000. Finally, Renaissance Technologies LLC purchased a new stake in Palvella Therapeutics during the 4th quarter valued at $256,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.